Sponsored by:

Molecular Imaging

FDA rejects NDA for Telix’s Pixclara
By AuntMinnie.com staff writers
The FDA has ruled that Telix's New Drug Application (NDA) for TLX101-CDx (Pixclara) cannot be approved in its current form.
April 29, 2025
Glioma Letters Brain
ARRS: 'Neurotheranostics' may be new frontier for nuclear medicine
By Will Morton
Advances in brain PET imaging combined with new treatments for Alzheimer’s have given rise to a new concept of "neurotheranostics."
April 29, 2025
A conceptual framework for neurotheranostics.
ARRS: Rib uptake evaluation on F-18 DCFPyL PET/CT presents challenges
By Maryam Payne
Evaluating increased rib uptake on F-18 DCFPyL PET/CT in prostate cancer patients may lead to false positives.
April 28, 2025
Pet Ct Machine
SPECT/CT predicts overall survival in Pluvicto patients
By Will Morton
New evidence supports using SPECT/CT scans along with serum PSA levels to evaluate early patient responses to Pluvicto treatment.
April 25, 2025
Patient examples of SPECT/CT and PET/CT RECIP 1.0. (A) SPECT and PET maximum-intensity projection (MIP) images in 74-year-old man with mCRPC. Serum PSA level at baseline was 449 ng/mL and slightly increased to 525 ng/mL after two cycles of Lu-177 PSMA. Eastern Cooperative Oncology Group (ECOG) score was 2 at baseline and increased to 3 after 2 cycles. The patient was classified by readers as RECIP-progressive disease on both SPECT and PET. Overall survival was 4.7 months. Two cycles of Lu-177 PSMA were administered. (B) SPECT and PET MIP images in 74-year-old man with mCRPC. Serum PSA level was 231 ng/mL at baseline and decreased to 12.5 ng/mL after 2 cycles of Lu-177 PSMA. ECOG score was less than 2 at baseline and after 2 cycles of Lu-177 PSMA. The patient was classified by readers as RECIP-partial response on both SPECT and PET. Overall survival was 14.3 months. Four cycles of Lu-177 PSMA were administered.
PET scans identify people at early risk for cognitive decline
By Will Morton
Amyloid PET scans in people with early signs of Alzheimer’s can identify those at higher risk of progressing to cognitive decline.
April 24, 2025
Ad Voxels Thumbnail
Eckert & Ziegler signs manufacturing deal with Pentixapharm
By AuntMinnie.com staff writers
Eckert & Ziegler Radiopharma GmbH has signed a manufacturing agreement with Pentixapharm.
April 24, 2025
Manufacturing Facility Process
UM launches new research reactor with $10M deal
By AuntMinnie.com staff writers
The University of Missouri (UM) has inked a $10 million deal with a Korean consortium.
April 23, 2025
Murr
Shine Technologies, Modawina Medical sign UAE distribution deal
By AuntMinnie.com staff writers
Shine Technologies has signed an agreement with Modawina Medical Company to distribute Shine’s lutetium-177 isotope in the UAE.
April 22, 2025
Atom Nuclear Lab 400
Combined PET scans predict the progression of Alzheimer’s disease
By Will Morton
Combining information from amyloid PET and FDG-PET scans can predict progression from mild cognitive impairment to Alzheimer's.
April 21, 2025
Ad Pet Fdg Thumbnail
PET scans predict outcomes for patients undergoing CAR T-cell therapy
By Will Morton
PET scans performed at one or three months after patients with large B-cell lymphoma begin CAR T-cell therapy can indicate whether they are responding to the treatment.
April 18, 2025
Pet Scan Patient
New theranostics PET tracer shows promise
By Will Morton
A new gallium-68 (Ga-68) PET/CT radiotracer appears superior over F-18 FDG for detecting bone metastases.
April 17, 2025
Images of a 69-year-old man diagnosed with prostate cancer who had a history of endocrine therapy for two years. (a) The maximum intensity projection (MIP) image of F-18 FDG showed moderate radiotracer uptake in a thoracic vertebra. (e) The MIP image of Ga-68 DOTA-IBA demonstrated more lesions in the cervical vertebra and pelvis. (b) An osteoblastic lesion in the C3 vertebra right attachment (curved arrows) was negative on F-18 FDG (SUVmax = 2.0) and positive on Ga-68 DOTA-IBA (SUVmax = 8.7). (c) Another osteoblastic lesion in the T10 vertebra left side (arrowheads) was both positive on F-18 FDG (SUVmax = 5.2) and positive on Ga-68 DOTA-IBA (SUVmax = 35.0). (d) Osteoblastic lesions in bilateral ilium (dotted arrows and arrows) were negative on F-18 FDG (left: SUVmax = 1.4, right: SUVmax = 1.6) and positive on Ga-68 DOTA-IBA (left: SUVmax = 7.6, right: SUVmax = 8.7). Follow-up imaging three months later confirmed the presence of these bone metastases. Image and caption available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Scientific Reports.
PET/CT detects vasculitis following COVID-19 vaccination
By Will Morton
A whole-body F-18 FDG-PET/CT scan was key in identifying medium-vessel vasculitis in a patient following a Moderna COVID-19 vaccination.
April 11, 2025
Covid 19 Vax Thumbnail
Page 1 of 603
Next Page